Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
BMO Capital analyst Etzer Darout maintains AstraZeneca (NASDAQ:AZN) with a Outperform and raises the price target from $80 t...
Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radioconjuca...
Wall Street suffers a double blow in Thursday’s session, as softer-than-expected revenue forecasts from Meta Platforms Inc. (NA...
AstraZeneca reports Q1 sales of $12.68 billion, up 17% Y/Y. Despite missing adjusted EPADS, oncology sees a 26% surge, driven b...
The back-and-forth motion in the market continues, with the index futures pointing to a lower opening on Thursday. Meta Platfor...
Guidance The Company reiterates its Total Revenue and Core EPS guidance for FY 2024 at CER, based on the average foreign excha...
